Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Krystal Biotech (KRYS)
NASDAQ:KRYS
Holding KRYS?
Track your performance easily
Earnings Data
Report Date
Mar 03, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
$1.18Last Year’s EPS
$0.3Same Quarter Last Year
Strong Buy
Based on 8 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 04, 2024
|% Change Since: -8.82%
|Next Earnings Date:Mar 03, 2025
Earnings Call Sentiment|Positive
The earnings call presented a strong financial performance with significant revenue growth and profitability. International expansion plans and pipeline advancements were well-received, though seasonal disruptions and litigation expenses posed challenges.Company Guidance
In the Krystal Biotech Q3 2024 earnings call, the company highlighted its strong financial performance and strategic progress. The net VYJUVEK revenue for the quarter was $83.8 million, contributing to over $250 million in total revenue since its launch in August 2023. The company achieved a gross margin of 92% and reported earnings per share of $0.95, up from $0.54 in the previous quarter, despite accruing $12.5 million in litigation expenses. The call also emphasized the successful expansion of VYJUVEK globally, with preparations for launches in Europe and Japan in 2025, and the company's robust pipeline with multiple clinical readouts expected soon. Krystal Biotech ended the quarter with $694.2 million in total cash and investments, demonstrating growing financial strength.Record VYJUVEK Revenue
Net VYJUVEK revenue for Q3 was $83.8 million, with total net revenue since launch surpassing $250 million.
Strong Profit Growth
Krystal reported a profit of $0.95 per share in Q3, up from $0.54 per share in Q2.
European and Japanese Expansion
Krystal is on track for a CHMP decision in Europe by year-end and expects a 2025 launch in Japan, with ongoing preparations for EU4, U.K., and Japan.
Positive Jeune Aesthetics' KB301 Readout
Clear efficacy signals in Q3 for KB301, propelling it towards a Phase II study next year.
Strong Cash Position
Krystal ended the third quarter with $694.2 million in total cash and investments, marking growth over the previous quarter.
---
KRYS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
KRYS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 04, 2024 | $176.39 | $170.85 | -3.14% |
| Aug 05, 2024 | $191.94 | $180.71 | -5.85% |
| May 06, 2024 | $161.10 | $156.94 | -2.58% |
| Feb 26, 2024 | $111.33 | $157.00 | +41.02% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Krystal Biotech (KRYS) report earnings?
Krystal Biotech (KRYS) is schdueled to report earning on Mar 03, 2025, TBA Not Confirmed.
What is Krystal Biotech (KRYS) earnings time?
Krystal Biotech (KRYS) earnings time is at Mar 03, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is KRYS EPS forecast?
KRYS EPS forecast for the fiscal quarter 2024 (Q4) is $1.18.
---